Benzinga | Sep 23, 2021 04:49AM EDT

Needham Initiates Coverage On Jazz Pharmaceuticals with Buy Rating, Announces Price Target of $220

Needham analyst Ami Fadia initiates coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy rating and announces Price Target of $220.